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PURPOSE AND SCOPE
This guideline covers the classification of ovulation disorders, treatment options of vari-
ous ovulation disorders, and their associated risks.
INTRODUCTION
Ovulation disorders account for 20% of the causes of subfertility.1 The goal of ovulation 
induction is to achieve development of a single follicle and subsequent ovulation in 
women with anovulation. The selection of the most appropriate treatment for ovula-
tion disorders depends upon reaching the correct diagnosis. Patients should be fully 
informed of the treatment options available, the success of each treatment option, and 
the associated risks.
CLASSIFICATION
Ovulation disorders can be classified according to the anatomical site where the hypo-
thalamic-pituitary-ovarian axis is deficient (Table 1). The corresponding World Health 
Organization (WHO) classification2 is also given for reference (Figure 1).
Adequate history and physical examination are essential. Further investigations 
are necessary to pinpoint where the defect in the hypothalamic-pituitary-ovarian axis is 
occurring. Based on the results of the investigation, the causes of anovulation can be 
divided into four distinct categories.3
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Hyperprolactinaemia
Hyperprolactinaemia can be found in 15% of wom-
en with anovulation, and in 75% of women with 
both anovulation and galactorrhoea.4 It interferes 
with the pulsatile secretion of gonadotrophin-re-
leasing hormone (GnRH) and impairs normal ovarian 
function. Causes of hyperprolactinaemia include a 
prolactin-producing adenoma, other tumours of the 
pituitary region blocking the inhibitory control of 
the hypothalamus, primary hypothyroidism, chronic 
renal failure, and a variety of drugs.
Prolactin molecules form irregular high-
molecular-weight polymers to produce a bio-
logically inactive form called macroprolactin. 
Macroprolactinaemia has no clinical significance 
and does not require any treatment. It should be 
considered in patients with no apparent hyperpro-
lactinaemic symptoms.5 The correct diagnosis can 
be made using prolactin chromatography and poly-
ethylene glycol immunoprecipitation. It has been 
suggested that routine screening for macroprolactin 
Table 1: Classification of ovulation disorders
1. Intrinsic ovarian failure (WHO group III)
    ? Genetic, autoimmune, following chemotherapy or  
  radiotherapy
2. Secondary ovarian dysfunction
a. Disorders of gonadotrophin regulation
Specific
    ? Hyperprolactinaemia
    ? Kallmann’s syndrome (WHO group I)
Functional (WHO group I)
    ? Weight loss, exercise, drugs, idiopathic
b. Gonadotrophin deficiency (WHO group I)
    ? Pituitary tumour, pituitary necrosis or thrombosis
c. Disorders of gonadotrophin action (WHO group II)
    ? Polycystic ovary syndrome
WHO = World Health Organization.
in sera from subjects with suspected hyperprolacti-
naemia is cost-effective and should be performed 
to prevent inaccurate diagnosis and unnecessary 
intervention for hyperprolactinaemia.6
Asymptomatic patients with hyperprolactinae-
mia may not require treatment, and periodic obser-
vation should then suffice. When a woman with a 
macroprolactinoma wishes to become pregnant, it 
is necessary to plan conception to occur after se-
rum prolactin is normalized and the tumour volume 
is significantly reduced in order to avoid or reduce 
the risk of compression of the optic chiasm during 
pregnancy.7
The first-line treatment is the use of dopa-
mine agonists, which lower prolactin concentration 
and cause shrinkage of a prolactinoma if present. 
Surgery in the form of trans-sphenoidal pituitary ad-
enomectomy is seldom indicated in the presence of 
a prolactinoma because of high recurrence rate and 
possibility of panhypopituitarism.8,9 Radiotherapy 
is used very infrequently and is considered only 
if both medical and surgical treatments fail or are 
contraindicated.
Hypergonadotrophic Hypogonadism (WHO 
Group III)
Hypergonadotrophic hypogonadism or ovarian fail-
ure may be due to chromosomal abnormalities, au-
toimmune disorders, infection (mumps oophoritis), 
and irradiation or cytotoxic drugs. Many cases, 
however, are idiopathic even after extensive in-
vestigations. These women present with primary 
or secondary amenorrhoea with low endogenous 
oestrogen and highly elevated follicle-stimulating 
hormone (FSH) levels. There is no advantage in 
performing laparoscopy and ovarian biopsy to de-
tect the presence of follicles in the resistant ovary 
syndrome because of the invasive nature and the 
doubtful value of the procedure.10,11
About half of young women with spontane
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Figure 1: Flowchart of diagnosis and treatment
ous hypergonadotrophic hypogonadism experience 
intermittent and unpredictable ovarian function, 
and spontaneous pregnancies have been reported 
in approximately 5–10% of cases subsequent to 
the diagnosis.12 Although there have been case re-
ports of successful ovulation induction treatment, 
any form of ovulation induction is not advisable 
in these women. The only realistic treatment for 
these patients is the use of donor eggs in an in 
vitro fertilization setting. In addition, they should 
be offered long-term hormone replacement therapy 
to protect their bones from the deleterious effects 
of hypooestrogenism.
Hypogonadotrophic Hypogonadism (WHO 
Group I)
These patients present with primary or secondary 
amenorrhoea. They have very low serum oestradiol 
concentration due to low FSH and luteinizing hor-
mone (LH) secretion from the pituitary gland (hypog-
onadotrophic hypogonadism). It can be due to either 
congenital causes such as Kallmann’s syndrome 
(isolated gonadotrophin deficiency and anosmia) or 
acquired causes such as pituitary tumour, pituitary 
necrosis (Sheehan’s syndrome), stress, and exces-
sive weight loss (anorexia nervosa).
Surgery is clearly indicated in patients with 
central nervous system tumours. Patients with ano-
rexia nervosa may benefit from psychotherapy and 
weight gain after extensive counselling. Pulsatile 
GnRH or gonadotrophins containing both FSH and 
LH13 are offered to patients with other hypogonado-
trophic causes or with persisting anovulation de-
spite weight gain.
Normogonadotrophic Anovulation (WHO 
Group II)
This includes a heterogeneous group of patients 
who can present either with regular cycles, oli-
gomenorrhoea, or even amenorrhoea. The mid-
FSH = follicle-stimulating hormone; GnRH = gonadotrophin-releasing hormone; TSH = thyroid-stimulating hormone.
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luteal serum progesterone is low, FSH levels are in 
the normal range, and prolactin is normal. Most of 
these patients are likely to have polycystic ovary 
syndrome (PCOS). Other causes include congenital 
adrenal hyperplasia, adrenal tumours, and andro-
gen-producing ovarian tumours. In these conditions, 
the patient may have clinical symptoms or signs of 
hyperandrogenism such as hirsutism, which should 
require more detailed investigations such as meas-
urement of dehydroepiandrosterone sulfate and 
17-hydroxyprogesterone.
Obese PCOS women will benefit from weight 
loss, as this might lead to resumption of sponta-
neous periods and ovulation and will also improve 
their response to ovulation induction. They usu-
ally respond well to clomiphene citrate (CC) or aro-
matase inhibitors, failing that, to gonadotrophins 
for ovulation induction. Insulin-sensitizing agents 
or laparoscopic ovarian drilling may be considered 
in those not responding to CC. Specific causes, such 
as adrenal or ovarian tumours, should be treated by 
removing the cause. Congenital adrenal hyperpla-
sia benefits from corticosteroid therapy.
TREATMENT
Effective use of ovulation induction agents requires 
understanding of their mechanism of action, proper 
indications, different regimens, monitoring meth-
ods, and potential complications.
Weight Reduction
Body mass index (BMI) is more representative of 
body fat and is calculated as weight in kilogrammes 
divided by height in metres squared. Overweight is 
defined as BMI ? 25 kg/m2 and obesity is BMI ? 
30 kg/m2.14 Overweight and obese women have a 
higher incidence of menstrual disturbance, ovula-
tion disorders, and subfertility.15 They may require 
higher dosage of ovulation drugs to achieve suc-
cessful ovulation but have lower ovulation rates 
and delayed responses to various treatments of 
ovulation induction, if needed.
Ovulation induction with CC in overweight and 
obese women results in lower ovulation rates16 and 
lower cumulative live birth rates for women with 
a BMI > 30 kg/m2.17 The dose of CC required to 
achieve ovulation is positively correlated with body 
weight.18 Ovulation rates following gonadotrophin 
therapy in overweight women are lower owing to 
higher cancellation rates,19,20 but this decreased 
success rate is not found in all studies.21 Women 
with BMI of 25–28 need a gonadotrophin dose 50% 
higher than normal-weight women.22 Obese women 
are also more prone to pregnancy complications 
such as miscarriage,23 gestational diabetes, hyper-
tension, macrosomia, and difficult delivery.24
Multiple observational studies report that 
weight loss is associated with improved spontane-
ous ovulation rates in women with PCOS,15 even af-
ter losing < 5% of body weight.25 Weight loss 
Patients seeking treatment for ovulation disorders should be 
fully informed of the treatment options available, the success 
of each treatment option, and the associated risks.
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is therefore recommended as first-line therapy in 
obese women with and without PCOS seeking preg-
nancy. This recommendation is based on extrapola-
tion from the benefits of weight loss seen in medi-
cal conditions, such as diabetes and cardiovascular 
disease. There is a paucity of studies suggesting 
that weight loss prior to conception improves live 
birth rate in obese women with or without PCOS.26
The guidelines for dietary and lifestyle inter-
vention in PCOS have been proposed.26 Lifestyle 
modification is the first form of therapy, combining 
behavioural (reduction of psychosocial stressors), 
dietary, and exercise management. Reduced-energy 
diets (500–1,000 kcal/day reduction) are effective 
options for weight loss and can reduce body weight 
by 7–10% over a period of 6–12 months. Structured 
exercise is an important component of a weight-
loss regime; aim for > 30 minutes per day. These in-
terventions should be conducted prior to pregnancy 
and not during ovulation induction, as the effects of 
calorie restriction and increased physical activity in 
the periconceptional period are unknown.27
Medical Induction of Ovulation
Dopamine Agonists
Three dopamine agonists, bromocriptine, cabergo-
line and quinagolide, are licensed for treatment of 
hyperprolactinaemia. Experience with bromocrip-
tine is far more extensive, and therefore for women 
undergoing ovulation induction this drug remains 
the treatment of choice, with cabergoline and quin-
agolide as acceptable second-line drugs in patients 
who are intolerant of bromocriptine.28
Mechanism of action. The secretion of 
prolactin from the lactotroph cells in the anterior 
pituitary gland is mainly regulated by the tonic 
inhibitory control of a prolactin inhibiting factor, 
which in humans is predominantly dopamine. Drugs 
with dopaminomimetic activity lower prolactin 
secretion, restore gonadal function, and shrink a 
prolactinoma, if present.
Regimen and monitoring. Bromocriptine is 
given at a daily dosage of 2.5–20 mg in divided dos-
es 2–3 times a day. Serum prolactin concentrations 
are regularly measured, and ovulation is checked 
by mid-luteal progesterone concentrations. Other 
forms of monitoring for ovarian response are not 
required, as its use is not associated with multiple 
pregnancy or ovarian hyperstimulation syndrome 
(OHSS).
Cabergoline and quinagolide have longer bio-
logical half lives than bromocriptine. Cabergoline 
can be taken once or twice weekly and quinagolide 
once daily.
In patients who do not ovulate even when 
prolactin concentrations are within normal range, 
dopamine agonists can be combined with anti-oes-
trogen or gonadotrophin as appropriate.
Results. Bromocriptine can normalize serum 
prolactin concentrations in 80–90% of patients 
with microprolactinomas and about 70% of those 
with macroprolactinomas, together with a decrease 
in tumour size.7,9 Dopamine agonist therapy restores 
ovulation in about 90% of women with anovulation 
related to hyperprolactinaemia.





the treatment of choice
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estimated rates of remission at 5 years in patients 
treated with bromocriptine were 76% among pa-
tients with non-tumoural hyperprolactinaemia, 67% 
among those with microprolactinomas, and 57% 
among those with macroprolactinomas.29
Cabergoline30,31 and quinagolide32,33 are shown 
to be significantly more effective than bromocrip-
tine in restoring normal prolactin concentrations 
and ovulatory cycles. Quinagolide is probably less 
effective than cabergoline in hyperprolactinaemic 
patients.28
It is recommended that the minimal length of 
dopamine agonist therapy in patients with prolacti-
noma should be 1 year.7 Normalization of magnetic 
resonance imaging prior to the withdrawal of do-
pamine agonists and longer duration of the drug 
therapy are significant predictors of remission.34 If 
a patient has normal prolactin concentrations after 
dopamine agonist therapy for at least 3 years and 
the tumour volume is markedly reduced, a trial of 
tapering and discontinuation of these drugs may 
be initiated. Long-term follow-up is essential with 
close monitoring for recurrent hyperprolactinaemia 
and renewed tumour growth.
Side-effects. Side-effects with bromocrip-
tine are common and include nausea, vomiting, 
abdominal cramps, vertigo, postural hypotension, 
headaches, and drowsiness. Although they are 
usually transient and mild, around 12% of pa-
tients discontinue the treatment for this reason.28 
The side-effects can be minimized by increasing 
the dose gradually from a low starting dose given 
with a meal in the evening, or by administering 
vaginal bromocriptine. A slow-release oral prepara-
tion may also reduce the incidence of side-effects. 
Significantly lesser side effects were reported in 
patients taking cabergoline and quinagolide when 
compared with bromocriptine.28
There is no increase in the incidence of mul-
tiple pregnancy, OHSS and spontaneous abortion 
with dopamine agonists.
Bromocriptine, cabergoline or quinagolide has 
not been associated with any detrimental effect on 
pregnancy or fetal development.28 It is still recom-
mended that patients with microprolactinomas or 
idiopathic hyperprolactinaemia stop bromocriptine 
treatment once pregnancy has been confirmed 
in order to avoid any potential harmful effects. 
Continuation of bromocriptine therapy during preg-
nancy may be considered in cases of macroprolacti-
noma or where there is evidence of tumour expan-
sion.7,9
While there is considerable experience of 
bromocriptine use in women undergoing ovula-
tion induction and during pregnancy, data on oth-
er dopamine agonists used in pregnancy are still 
limited.
The European Medicines Agency has recom-
mended new warnings and contraindications for 
ergot-derived dopamine agonists as a result of the 
risk of fibrosis, particularly cardiac fibrosis, associ-
ated with chronic use. Cardiac valvulopathy should 
be excluded by echocardiography before treatment 
with cabergoline or bromocriptine, and patients 
should be monitored during treatment.35 Women 
who are planning pregnancy are further advised to 




Clomiphene citrate is commonly used as the first-
line drug in women who suffer from normogonado-
trophic anovulation (WHO group II).
Mechanism of action. It is an orally active 
non-steroidal compound with both oestrogenic and 
anti-oestrogenic properties with its primary mecha-
nism of action based on the anti-oestrogenic prop-
erty. It displaces endogenous oestrogen from oes-
trogen receptors in the hypothalamic-pituitary axis, 
which diminishes its negative feedback and 
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increases the secretion of GnRH and thus gonado-
trophins. The increase in FSH and LH stimulate the 
production of ovarian follicles and subsequent ovu-
lation.
Regimen and monitoring. CC should be 
started at 50 mg per day for 5 days following a 
spontaneous or progestin-induced withdrawal 
bleeding. The recommended maximum dose is 150 
mg per day as there was no clear evidence of ef-
ficacy at higher doses and the US Food and Drug 
Administration (FDA) recommended a maximum of 
750 mg per treatment cycle.27 Starting from day 2, 
3, 4 or 5 of the cycle was not shown to influence 
the results.36
Ovulation usually occurs within 5–10 days 
after the last tablet. If there is no ovulation, the 
dose is increased at increments of 50 mg per cycle 
until ovulation occurs, or a maximum dose of 150 
mg daily is reached.
While 50 mg per day is the recommended dose 
in the first cycle, a meta-analysis of 13 published 
reports suggests that only 46% will ovulate at this 
dose, a further 21% will respond to 100 mg and 
another 8% will ovulate with 150 mg per day.37
Although results of large trials suggest that 
monitoring by ultrasound or progesterone is not 
mandatory to ensure good outcome,17 it is recom-
mended to monitor the response at least during the 
first treatment cycle to ensure that an appropriate 
dose is received.38 Transvaginal pelvic ultrasound 
should be used to monitor follicular growth and 
endometrial thickness. Patients who have no or 
excessive response to the current dose of CC and 
show reduced endometrial thickness can be identi-
fied. Serum progesterone concentrations could also 
be measured in mid-luteal phase to check for ovula-
tion.
Duration of treatment. Treatment should 
generally be limited to six (ovulatory) cycles.39 A 
course of six ovulatory cycles is usually sufficient 
to know if pregnancy will be achieved. Studies have 
reported that 71–87.5% of pregnancies achieved 
with CC occur within the first three cycles of treat-
ment.16,40,41
Further cycles (with a maximum of 12 in to-
tal) may be considered on an individual basis after 
discussion with the patient. However, second-line 
treatment should be considered for patients not 
conceiving after six ovulatory cycles of CC.
Further use of CC beyond 12 cycles has been 
found to be associated with an increased risk of 
ovarian cancer (relative risk [RR], 11.1; 95% confi-
dence interval [CI], 1.5–82.3)42 and is thus not rec-
ommended.
Results. A compilation of published results 
from 5,268 patients revealed an ovulation rate of 
73% per patient, pregnancy rate of 36% per pa-
tient, and live birth rate of 29% per patient.39
A Cochrane meta-analysis43 of three stud-
ies44–46 comparing CC versus placebo in patients 
with anovulatory subfertility showed a large and 
consistent benefit of CC compared with placebo 
(odds ratio [OR], 5.77; 95% CI, 1.55–21.48; P < 
0.009). Analysis for ovulation rate (per woman) also 
The goal of ovulation induction is to achieve development 
of a single follicle and subsequent ovulation in women with 
anovulation.
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showed a benefit of CC compared with placebo (OR, 
7.47; 95% CI, 3.24–17.23; P < 0.00001). There is 
no increase in spontaneous abortion or congenital 
abnormalities in CC-induced pregnancies.
CC in combinations. One small randomized 
controlled trial (RCT)47 of 20 participants compar-
ing CC (50 mg) plus tamoxifen (20 mg) versus CC 
(100 mg) alone showed no significant differences 
in pregnancy (OR, 3.32; 95% CI, 0.12–91.60) and 
ovulation rate (OR, 14.54; 95% CI, 0.67–316.69) 
between the two groups. There were no instance 
of OHSS in either group, and all pregnancies were 
singleton.
One RCT48 comparing CC (up to 150 mg) plus 
ketoconazole 400 mg with CC alone showed no 
evidence of difference in pregnancy rate (OR, 2.37; 
95% CI, 0.88–6.40), multiple pregnancy rate (OR, 
1.18; 95% CI, 0.37–3.78), and miscarriage rate (OR, 
0.28; 95% CI, 0.01–7.08).
One RCT49 comparing CC (200 mg) plus bro-
mocriptine (7.5 mg) versus CC (200 mg) showed no 
evidence of difference in pregnancy (OR, 0.98; 95% 
CI, 0.33–2.96) and ovulation rate (OR, 1.33; 95% CI, 
0.47–3.79).
Analysis of three RCTs50–52 comparing CC (50–
200 mg) plus dexamethasone (0.5–2.0 mg) with CC 
(50–200 mg) showed a large and consistent ben-
efit of pregnancy rate in the CC plus dexametha-
sone group (fixed OR, 9.46; 95% CI, 5.05–17.7; P < 
0.00001). When the study50 using 0.5 mg was ex-
cluded and only the two studies51,52 using 2 mg were 
analysed, the OR was 25.3 (95% CI, 13.7–46.6; P 
< 0.00001) in favour of CC plus dexamethasone. 
There was no significant difference in the incidence 
of multiple pregnancies per women (OR, 7.71; 95% 
CI, 0.38–155.64). No side effects were reported in 
either group.
One RCT53 comparing CC (100 mg) plus com-
bined oral contraceptive pills which are given for 
1 month prior to CC versus CC (100 mg) showed a 
benefit of CC plus combined pills in the pregnancy 
rate (OR, 27.18; 95% CI, 3.14– 235.02) and the 
number needed to treat (NNT) was 2.0 (95% CI, 
1.4–3.4). Ovulation rate also showed a benefit in 
favour of CC plus combined pills (fixed OR, 26.71; 
95% CI, 4.91–145.38) and the NNT was 1.6 (95% CI, 
1.2–2.4). There was no evidence of difference in 
miscarriage rate (OR, 1.0; 95% CI, 0.06–16.97) or 
multiple pregnancy rate per woman (OR, 7.98; 95% 
CI, 0.39–163.33) between the two groups.
Analysis of two RCTs54,55 showed no signifi-
cant difference in pregnancy rate between the two 
groups with or without human chorionic gonadotro-
phin (hCG) (OR, 1.18; 95% CI, 0.59–2.36). There was 
also no difference in the incidence of spontaneous 
abortion or miscarriage reported (OR, 0.70; 
Most patients with normogonadotrophic anovulation are likely to have polycystic ovary syndrome.
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95% CI, 0.19–2.62). Multiple pregnancy rate was 
reported in one study,55 which showed no signifi-
cant difference (OR, 2.21; 95% CI, 0.19–24.98)
One RCT56 showed no significant difference 
for ovulation rate (OR, 1.34; 95% CI, 0.42–4.27), 
pregnancy rate (OR, 0.42; 95% CI, 0.07–2.46) or in-
cidence of adverse events between the groups with 
or without hormone supplementation.
Failure of CC treatment. Women who do not 
ovulate while receiving the 150 mg dose are con-
sidered to be CC-resistant. Inability of CC to induce 
ovulation is more likely in patients who are obese, 
insulin-resistant and hyperandrogenic compared 
with those who do respond.16
Only about 50% of women who ovulate with 
CC will conceive. This may be partly explained by 
the peripheral anti-oestrogenic effect of CC at the 
level of endometrium and cervical mucus or by hy-
persecretion of LH. The two most common causes 
of failure to conceive in response to CC are the 
presence of other subfertility factors and the failure 
to persist with repeated attempts.
Side effects. Side effects of CC are related 
to its combined oestrogenic and anti-oestrogenic 
properties, which include hot flushes, breast dis-
comfort, abdominal distension, nausea, vomit-
ing, nervousness, sleeplessness, headache, mood 
swings, dizziness, hair loss, and disturbed vision. 
CC is usually very well tolerated with the side ef-
fects being dose-dependent and usually completely 
reversible once CC is stopped.
Approximately 7% of pregnancies resulting from 
CC-induced ovulation are twin pregnancies, and 
0.5% are triplet pregnancies.57 While mild ovarian 
enlargement is relatively common, severe OHSS is 
very rare.
Tamoxifen
Tamoxifen is a triphenylethylene derivative with a 
structure similar to CC. The suggested dose in ovu-
lation induction is 20–40 mg daily, beginning on 
cycle day 3 for 5 days.
A meta-analysis58 including four RCTs59–62 
comparing tamoxifen and CC showed similar ovula-
tion rates (OR, 0.755; 95% CI, 0.513–1.111). There 
were no significant differences in pregnancy rate 
per cycle (OR, 1.056; 95% CI, 0.583–1.912) and per 
ovulatory cycle (OR, 1.162; 95% CI, 0.632–2.134) 
between the two groups. 
There were no instances of OHSS or multiple 
pregnancies, and there was no difference in the in-
cidence of miscarriage in one trial60 reporting this 
outcome (OR, 0.37; 95% CI, 0.01–9.45).
While efficacy and safety of tamoxifen in ovu-
lation induction has been shown, tamoxifen is not 
licensed for that purpose and patients should be 
counselled for its off-label use.
Insulin-sensitizing Agents
Mechanism of action. Insulin resistance is one 
of the recognized metabolic disturbance associated 
with PCOS, and may arise from either genetic de-
fects or obesity. Insulin-sensitizing agents increase 
the insulin responsiveness in target tissues and 
hence reduce the compensatory hyperinsulinaemia, 
thereby ameliorating the associated metabolic ef-
fects. They include the biguanides and thiazolidin-
ediones.
Metformin is one of the most commonly used 
biguanide. It does not stimulate insulin release and 
hence does not cause hypoglycaemia when used 
alone. In PCOS patients, it has been shown to im-
prove glucose tolerance and lipid profiles, and de-
crease proinflammatory markers.
Regimen. Five hundred milligrams thrice daily 
or 850 mg twice daily with meals.
Efficacy. A recent Cochrane review63 as-
sessed the effectiveness of insulin-sensitizing 
drugs in fertility treatment for women with PCOS.
Metformin monotherapy. Metformin used 
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alone improves the ovulation rate (OR, 2.12; 95% 
CI, 1.5–3.0) and clinical pregnancy rate (OR, 3.86; 
95% CI, 2.18–6.84) compared with placebo or no 
treatment, but not the live birth rate (OR, 1.0; 95% 
CI, 0.16–6.39).
Compared with CC, metformin gives lower ovu-
lation rate (OR, 0.48; 95% CI, 0.41–0.57) and clinical 
pregnancy rate (OR, 0.63; 95% CI, 0.43–0.92), and 
a non-significant trend of lower live birth rate (OR, 
0.67; 95% CI, 0.44–1.02). There are no difference in 
the miscarriage rate (OR, 0.94; 95% CI, 0.42–2.07) 
and the multiple pregnancy rate (OR, 0.33; 95% CI, 
0.02–6.69) between the two treatments.
Metformin co-treatment with CC. Co-
treatment with metformin and CC improves the ovu-
lation rate (OR, 1.76; 95% CI, 1.51–2.06) and clini-
cal pregnancy rate (OR, 1.48; 95% CI, 1.12–1.95), 
but not live birth rate (OR, 1.05; 95% CI, 0.75–1.47) 
compared with CC alone.
Previous subgroup meta-analyses indicated a 
higher clinical pregnancy rate after co-treatment 
with metformin and CC compared with CC alone in 
obese patients only (OR, 3.72; 95% CI, 1.23–11.22) 
but not in non-obese patients (OR, 2.71; 95% CI, 
0.96–7.63), and in CC-resistant subjects only (OR, 
9.62; 95% CI, 2.95–31.45).64
Another systematic review65 also indicated 
that metformin plus CC led to higher live birth 
rates than CC alone only in CC-resistant women 
(RR, 6.44; 95% CI, 1.19–34.90) but not in CC-naive 
women (RR, 1.04; 95% CI, 0.82–1.33).
Side effects. Side effects include dose-de-
pendent gastrointestinal upset including nausea, 
vomiting, and diarrhoea. Lactic acidosis is a rare 
though serious complication, and hence metformin 
should not be prescribed to patients with renal, he-
patic or major cardiovascular disease or hypoxia.
Use of other insulin-sensitizing agents 
in PCOS patients. Examples include rosiglitazone 
and pioglitazone. It was shown that rosiglitazone 
improved ovulation rate (OR, 31.0; 95% CI, 3.76–
255.30) but result in a higher incidence of weight 
gain.63 On the other hand, these drugs are classified 
as FDA category C. There are no data on the role of 
pioglitazone in fertility treatment.
Aromatase Inhibitors
Aromatase inhibitors have been used for many 
years as an adjunct treatment for breast cancer and 
are gaining in popularity as an agent for ovulation 
induction in patients with PCOS. Its use in combi-
nation with gonadotrophin in ovarian stimulation 
protocol for patients, in whom high oestradiol level 
would be contraindicated, for example breast can-
cer patients, is also advocated.
Letrozole is a third-generation aromatase in-
hibitor and is the most commonly used agent in 
ovulation induction. When compared with CC, letro-
zole does not have the anti-oestrogenic effects and 
has a much shorter half-life. However, the use in 
ovulation induction is an off-label use.
Mechanism of action. Aromatase catalyses 
the rate-limiting final step in oestrogen production, 
the hydroxylation of androstenedione to oestrone 
and of testosterone to oestradiol. By blocking 
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oestrogen production, it increases FSH secretions 
with a decrease in the oestrogenic negative feed-
back of the hypothalamic-pituitary axis. Because 
aromatase inhibitors block high levels of oestrogen 
from androgen conversion, the effects in women 
with PCOS are more prominent.
Regimen and monitoring. The regimen is 
2.5 to 5 mg per day for 5 days from days 3–7 of the 
period66–68, or as a single dose of 20 mg on day 3 of 
the period.69 A prolonged duration for 10 days has 
been evaluated.70
The monitoring is similar to that of CC and 
usually starts on day 7 of menses. Further monitor-
ing depends on the growth of the follicles. With the 
split-dose regimen, multiple developing follicles 
appear on cycle day 7, but at mid-cycle only a single 
dominant follicle is found.
Results. In a review,71 letrozole gave an ovu-
lation rate of 70–84% and a pregnancy rate of 
20–27% per cycle in PCOS women resistant to CC. 
Both of the single-dose and split-dose regimens 
achieved similar clinical pregnancy rates.69 More 
follicles developed and a higher clinical pregnancy 
rate were reported in the longer letrozole regimen 
(2.5 mg daily for 10 days) when compared with the 
standard regimen (5 mg daily for 5 days).70
Other aromatase inhibitors have been com-
pared with letrozole. In a prospective study,72 22 
PCOS women were assigned to letrozole (2.5 mg 
per day for 5 days) and 18 to anastrozole (1 mg per 
day for 5 days). Letrozole was associated with a 
significantly higher ovulation rate (84.4% vs 60.0%) 
and pregnancy rate (27.0% vs 16.6%) than anas-
trozole.
Comparison with other methods. A meta-
analysis73 of four prospective, randomized stud-
ies68,74–76 revealed that the overall effects of letro-
zole in comparison with CC was not significant for 
ovulatory cycles (OR, 1.17; 95% CI, 0.66–2.09), 
pregnancy rate per cycle (OR, 1.47; 95% CI, 0.73–
2.96) and pregnancy rate per patient (OR, 1.37; 95% 
CI, 0.70–2.71).
Ovulation disorders account for 20% of the causes of subfertility.
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In a Cochrane review77 on different ovarian 
stimulation protocols in intrauterine insemination 
treatment, five studies comparing CC with letrozole 
also found no significant difference in the pregnan-
cy rate (OR, 1.2; 95% CI, 0.64–2.1).
Side effects. Letrozole is well tolerated. 
Fatigue, nausea, constipation, diarrhoea, headache, 
drowsiness and dizziness are common side effects.
The multiple pregnancy rate was significantly 
lower in letrozole, both 2.5 mg daily or 5 mg daily, 
compared with CC treatment, as the letrozole treat-
ment gave more monofollicular development com-
pared with CC as shown by earlier reports. However, 
in the recent RCT78 on the pregnancy outcome after 
CC or letrozole treatment, the chance of twin preg-
nancies of letrozole was comparable to that of CC 
(8.3% vs 9.1%). There was also a case report of a 
triplet pregnancy resulting from ovulation induction 
in a PCOS woman resistant to CC treatment.79
The teratogenic effects of letrozole are well 
described in animal studies.80,81 Biljan et al82 in an 
abstract suggested that the use of letrozole for sub-
fertility treatment might be associated with a high-
er risk of congenital cardiac and bone malforma-
tions in the newborns. In a retrospective study with 
a much larger sample size, Tulandi et al83 could not 
show any difference in the overall rates of major 
and minor congenital malformations among new-
borns from mothers who conceived after letrozole 
or CC treatments.
Gonadotrophin-releasing Hormone
Mechanism of action. GnRH administered in a 
pulsatile fashion restores the normal pattern of 
gonadotrophin secretion of a spontaneous men-
strual cycle, leading to the development of a single 
dominant follicle.
Regimen and monitoring. Pulsatile GnRH 
is given by the subcutaneous or intravenous route 
through a small butterfly cannula using a small bat-
tery-operated pump which delivers 2.5–20.0 μg per 
bolus at 60–120-minute intervals. The intravenous 
route is preferred by some, because more physio-
logical LH profiles and higher ovulatory rates result 
when GnRH is administered intravenously.84 Higher 
dosage (10 μg per bolus) given at lower intervals 
(120 minutes) are just as effective as lower dos-
age (2–5 μg per bolus) given at a higher rate (every 
60–90 minutes).85
Treatment can be monitored by regular serum 
oestradiol measurements and pelvic ultrasound at 
regular intervals. Couples are advised to have regu-
lar intercourse during the treatment cycle. The lu-
teal phase has to be supported, either by continuing 
with the same regimen of pulsatile GnRH adminis-
tration or using exogenous hCG injections.
Results. Hypogonadotrophic patients of nor-
mal or low weight are the best candidates for this 
treatment. A cumulative pregnancy rate of 80% 
after six cycles and up to 93% after 12 has been 
reported.86 It is recommended to continue this ther-
apy for at least 12 cycles in the absence of other 
subfertility factors.
A Cochrane review did not find any evidence 
to show the effectiveness of pulsatile GnRH in 
women with PCOS.87
Side-effects. Multiple pregnancy rates 
ranged between 3.8–13.5%.88–91 The risk of mul-
tiple pregnancy is predominantly present in the 
first cycle and is related to higher pulse dosages.88 
Therefore, this risk can be greatly reduced if lower 
pulse dosages are employed at a lower frequency 
for the first cycle.
OHSS has never been described with pulsatile 
GnRH administration.
Patients may be reluctant to use the pulsatile 
GnRH therapy because of inconvenience, worry 
about pump failure and the problems of the needle 
being left in situ for a long time (eg, displacement, 
local reaction, infection). As a result, it is used in 
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very few patients for whom alternatives such as 
gonadotrophin treatment are available.
Gonadotrophin (Table 2)
Human menopausal gonadotrophins are extracted 
from urine of postmenopausal women. Besides the 
difficulty in collecting urine, urinary gonadotrophins 
contain other non-FSH urinary proteins and hence 
the higher incidence of local allergic reactions and 
batch-to-batch inconsistency. Recombinant human 
FSH is a pure FSH preparation, devoid of the dis-
advantages associated with urinary gonadotrophins 
and allows self subcutaneous injection, but is gen-
erally more expensive. There is no difference be-
tween urinary FSH and recombinant human FSH in 
ovulation and pregnancy rates, as well as in the in-
cidence of miscarriage, OHSS, multiple pregnancy 
and duration of stimulation.92
Mechanism of action. The use of exogenous 
gonadotrophins is to overcome the FSH threshold 
required for the follicular development.
FSH is the key gonadotrophic hormone during 
the follicular phase and only minute amounts of 
LH are needed in different stages of follicular de-
velopment and function. However, in women with 
hypogonadotropic hypogonadism, a preparation 
containing both FSH and LH gives better outcome 
than purely FSH93 because of the fundamental role 
of LH in ovarian steroidogenesis to produce an ad-
equate serum oestradiol concentration for optimal 
endometrial proliferation.
Regimens. (a) Chronic low-dose, step-up 
protocol. This is currently the recommended pro-
tocol in many centres worldwide. The principle is 
to determine the FSH threshold gradually, avoiding 
excessive stimulation and multifollicular develop-
ment. FSH is commenced at a low starting dose 
(37.5–75 IU/day) for at least 10–14 days27 and 
the daily dose is increased by 37.5 IU at weekly 
intervals up to a maximum of 225 IU/day if there 
is no evidence of ovarian response. The same dose 
is maintained once follicular growth is observed. 
Once one to two dominant follicles reach 18 mm 
in mean diameter, hCG is administered at a dose of 
5,000–10,000 IU to induce ovulation. The couple is 
advised to have intercourse on the day of hCG injec-
tion and on the following day.
As it may take several weeks to achieve an 
ovarian response in those with a high FSH thresh-
old, patients should be counselled about the time 
scale prior to the first treatment cycle. In subse-
quent cycles, the patient can then be started at a 
dose that gives rise to ovarian response in the first 
cycle and this will shorten the duration required.
Table 2. Different gonadotrophin preparations 






HMG Urine 75 75 95%
Urinary FSH Urine 75 < 0.7 95%
Urinary FSH – high 
purity
Urine 75 < 0.001 < 1%
Recombinant FSH Chinese hamster ovary 50, 75, 100, 150, 200 None None
FSH = follicle-stimulating hormone; HMG = human menopausal gonadotrophin.
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An original approach was the ‘conventional 
dose step-up’ regime, where gonadotrophin is com-
menced at 150 IU/day and stepped up by increments 
of 75 IU every 4 to 5 days till ovarian response is 
evident.94 Compared with the ‘chronic low-dose 
step-up’ approach, the duration of stimulation is 
shorter but the incidence of multiple pregnancy and 
ovarian hyperstimulation is higher, especially in pa-
tients with PCOS.
(b) Step-down protocol. The aim of this pro-
tocol is to mimic the physiological changes of nor-
mal cycles. Gonadotrophin injection is commenced 
at 150 IU/day starting on day 2–3 of the cycle, and 
the ovarian response is monitored by transvaginal 
scanning every 2–3 days. The same dose is con-
tinued until a dominant follicle ? 10 mm is seen 
on scanning, and is then reduced to 112.5 IU/day 
followed by a further decrease to 75 IU/day 3 days 
later, which is continued until hCG is administered 
to induce ovulation. Hence, it requires more intense 
monitoring than the step-up protocol.
According to the largest randomized trial,95 
the step-down regime has a shorter duration of 
stimulation compared with the step-up protocol but 
a higher rate of multifollicular development and 
OHSS, as well as a lower ovulation rate. The preg-
nancy rate is comparable between the two regimes.
Monitoring. Ovarian response is monitored 
during gonadotrophin treatment to allow for adjust-
ment of the gonadotrophin dose, timing the hCG 
injection for ovulation trigger, and cancellation of 
cycles with excessive response. Both serum oestra-
diol concentrations and ultrasound examination are 
commonly used for monitoring purposes. Serum 
oestradiol concentration reflects the total amount 
of oestradiol secreted from growing follicles but 
not the precise number of follicles. Ultrasound ex-
amination gives an immediate result of the number 
of dominant follicles and their sizes. Sholam et al96 
has shown that oestradiol concentrations did not 
add any additional information to the monitoring 
solely based on ultrasound.
Concomitant use. (a) With GnRH agonists. 
High LH concentrations commonly found in the fol-
licular phase of patients with PCOS are associated 
with an increased rate of spontaneous abortion. 
Premature luteinization may occur in some patients 
before the dominant follicle reaches 16–18 mm in 
mean diameter. The use of GnRH agonists (GnRH-a) 
prior to gonadotrophin administration will lower 
the tonic high LH concentrations during the follicu-
lar phase and prevents the occurrence of premature 
LH surges. This may be used in patients with a pre-
vious history of premature luteinization. However, 
a meta-analysis97 of three randomized trials shows 
that there is no clear advantage in the routine use 
of GnRH-a in conjunction with gonadotrophin for 
ovulation induction in patients with CC-resistant 
PCOS. Common odds ratios for pregnancy per treat
?????????????????? ?? 
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ment cycle and moderate to severe OHSS are 1.5 
(95% CI, 0.72–3.12) and 1.40 (95% CI, 0.5–3.92), 
respectively. Moreover, the use of GnRH-a will fur-
ther increase the cost of gonadotrophin treatment 
because of the GnRH-a and the increased amount 
of gonadotrophins used after using GnRH-a.
(b) With CC. A combination of CC and gon-
adotrophin has been used to lessen the overall cost 
by reducing the amount of gonadotrophin needed. 
CC is used initially (100 mg daily from days 2–6) 
for follicular recruitment, followed by gonadotro-
phin (150 IU daily or on alternate days) to promote 
follicular growth, thus reducing the gonadotrophin 
requirement by up to 50%. This regimen is only of 
use in anovulatory patients who have endogenous 
gonadotrophins.
Results. The 6-month cumulative pregnancy 
rate in non-PCOS patients is around 90% with a 
miscarriage rate of 25%, whereas the correspond-
ing rate in PCOS is only 50–60% with a miscarriage 
rate of 30–40%. Conventional dose step-up proto-
col in PCOS patients leads to 5% severe OHSS rate 
and 34% multiple pregnancy rate. When chronic 
low-dose step-up protocol is used in these women, 
similar pregnancy rates are achieved but the rates 
of severe OHSS and multiple pregnancy can be re-
duced to < 0.1% and 6%, respectively.
Side-effects. Serious complications of gon-
adotrophin therapy include OHSS and multiple 
pregnancy. Other complications include local reac-
tion at the site of the injection or, rarely, anaphy-
lactic reaction, perhaps due to the protein content 
of the urinary products. Such patients should be 
switched to recombinant FSH preparations.
Surgical Induction of Ovulation
Laparoscopic ovarian drilling is the preferred sur-
gical method of ovulation induction over ovarian 
wedge resection, which is associated with a higher 
risk of postsurgical adhesion formation, converting 
hormonal subfertility to mechanical subfertility.
Mechanism of action. The mechanism of ac-
tion of LOD is thought to be related to the destruc-
tion of ovarian androgen-producing tissue and the 
decrease of the peripheral conversion of androgens 
to oestrogens. A fall in the serum concentrations of 
androgens and LH and an increase in FSH concen-
trations have been demonstrated after LOD.
Regimen and monitoring. Electrocautery 
is commonly used in LOD. The procedure includes 
penetration of the ovarian capsule, making four 
punctures per ovary, and electrocautery is given 
at a power setting of 30 W applied for 5 seconds 
per puncture.98,99 Another commonly used method 
is laser vaporization using carbon dioxide, argon or 
Nd:YAG crystal lasers.
Results. The ovulation rate after LOD in CC-
resistant PCOS women was 52% to 67%.100 The 
ovulation rate in PCOS women with LOD as the 
first-line treatment was 64%.101 The pregnancy rate 
after LOD in CC-resistant PCOS women was 67%.99
Comparison with other methods. The theo-
retical advantages of LOD are multiple attempts of 
pregnancy allowed, monofollicular development, 
reduced miscarriage rate with the normalized hor-
monal profile, and assessment of the pelvic pathol-
ogy and tubal status at the same setting. 
LOD is usually the second-line treatment 
modality for PCOS women who fail to respond to 
CC, and so the comparison is usually with ovula-
tion induction with gonadotrophins. In a Cochrane 
review,100 the live birth rate of LOD is comparable 
to three cycles of gonadotrophins (OR, 0.68; 95% 
CI, 0.15–3.10) after 6 months of follow-up or six 
cycles of gonadotrophins at 12 months’ follow-up 
(OR, 1.12; 95% CI, 0.60–2.08), with the pooled OR 
being 1.04 (95% CI, 0.59–1.83). There was no dif-
ference in the miscarriage rate between LOD and 
gonadotrophin therapy. The multiple pregnancy rate 
was reduced in the patients with LOD, with com
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parison of ovarian drilling with or without medical 
ovulation and gonadotrophins only (OR, 0.13; 95% 
CI, 0.03–0.59). There was no OHSS reported in the 
randomized trials in the LOD groups. There was no 
difference in ovulation rate and clinical pregnancy 
rate after unilateral or bilateral ovarian drilling.
Based on an economic evaluation by Farquhar 
et al,102 the cost of a live birth in PCOS women re-
sistant to CC using LOD would be one-third lower 
than using urinary or recombinant gonadotrophin 
treatment cycle.
LOD has been compared with CC treatment 
as the first-line treatment in a randomized study.101 
The pregnancy rate was higher in the CC group 
(44%) than the LOD group (27%), although the dif-
ference did not reach statistical significance (OR, 
2.1; 95% CI, 0.7–5.8). The conclusion was that LOD 
was not superior to CC as a first-line method of 
ovulation induction in women with PCOS.
Side-effects. The main drawback of LOD is 
the need for general anaesthetic and surgery. Other 
complications such as adhesion formation and the 
risk of premature ovarian failure are of concern. 
The reported incidence of adhesion formation after 
LOD varied considerably in different studies from 
0% to 100%.103–105 Most of the studies reported 
mild to moderate adhesions in about 35% of cases, 
which did not seem to affect the pregnancy rate 
after LOD.104
?????? ?? ?????? ????????? ?
Multiple Pregnancies
In the last two decades, significant increase in 
the incidence of multiple births is almost entirely 
the result of the use of gonadotrophins and other 
agents for ovulation induction or assisted concep-
tion.
Spontaneous multiple pregnancies occur 
in about 1–2% of women, which is increased to 
7–10% of women taking CC and further increased 
to up to ~25% in women with CC-resistant PCOS 
treated with gonadotrophins.106
Multiple pregnancies carry extra risks for 
both the mothers and fetuses. Obstetric complica-
tions include increased incidence of pre-eclampsia 
and eclampsia, antepartum haemorrhage, preterm 
labour, and surgical or assisted delivery. The high 
incidence of prematurity and low birth weight in 
high-order multiple pregnancies result in a fourfold 
rise of perinatal mortality for twins and sixfold rise 
in triplets compared with singleton pregnancies. 
Multiple-gestation children may suffer long-term 
consequences of perinatal complications, includ-
ing cerebral palsy and learning disabilities, as well 
as slow language development and behavioural 
problems.
In order to reduce the incidence of iatrogenic 
multiple pregnancies and its subsequent risks, ovu
The incidence of spontaneous multiple pregnancies is increased 
in women taking clomiphene citrate and further increased 
in those with clomiphene citrate-resistant polycystic ovary 
syndrome treated with gonadotrophins.
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lation induction should aim to restore the feedback 
system, which selects a single follicle for ovulation.
Hyperprolactinaemic women should be 
treated with dopamine agonists and women with 
hypogonadotrophic hypothalamic amenorrhoea 
should be treated with pulsatile GnRH if possible, 
which is associated with a high incidence of single 
ovulation.
For women with normogonadotrophic anovula-
tion, including PCOS, the first-line treatment is CC 
and the ovarian response should be monitored by 
pelvic ultrasound especially in the first cycle or af-
ter the dose of CC has been stepped up. Incidence 
of twins is increased to 7–10% and that of triplets 
is 0.5–1%.57
Treatment with gonadotrophins should be 
confined to those who are resistant to CC, because 
multiple pregnancy is considerable (~25–36%) 
with the conventional ‘step-up’ regimens.106 Low-
dose ‘step-up’ or ‘step-down’ regimens should be 
encouraged, since they aim to maintain the physi-
ological principle of follicle selection resulting in a 
high incidence of monovulation, though at the price 
of slightly lower pregnancy rates.107
Patients at risk of multiple follicular develop-
ment, eg, patients with PCOS, should be identified. 
A lower starting dose of gonadotrophin should be 
used. Ovarian response should be carefully moni-
tored with ultrasound examinations in terms of 
the size and number of developing follicles. Cycles 
with more than two dominant follicles should be 
cancelled and the starting dose should be reduced 
in subsequent cycles. Alternatively, the ovulation 
induction cycles could be converted to in vitro fer-
tilization treatment with replacement of at most 
two embryos only. Supernumerary follicles could 
be aspirated and selective fetal reduction could be 
considered to help in reduction of multiple preg-
nancies. However, selective fetal reduction is not 
without complications, and it should never be con-
sidered a substitute for careful monitoring.
Ovarian Cancer
Epithelial ovarian cancer is the most life-threaten-
ing gynaecological cancer, with a low 5-year sur-
vival rate estimated at 30–35% when all stages 
are taken together.108 Epidemiological studies have 
linked epithelial ovarian cancer with both nullipar-
ity and subfertility.
Increasing concerns have been raised regard-
ing the risk of ovarian malignancy during or after 
ovarian stimulation. A cohort study42 indicated a 
RR of 11.1 (95% CI, 1.5–82) with long-term use of 
CC (12 months or more). A collaborative analysis of 
12 US case-control studies109 also showed an in-
creased risk (OR, 2.8; 95% CI, 1.3–6.1) of invasive 
ovarian cancer in subfertile women who had used 
fertility drugs compared with women who were not 
subfertile.
Two hypotheses have postulated ovulation as 
potential biological promoters of ovarian cancer and 
thus increased risks of ovarian cancer with fertil-
ity drugs used in ovulation induction or stimulation. 
The most widely accepted hypothesis suggests that 
epithelial ovarian carcinoma results from repeated 
ovulations, where the cumulative effects of each 
minor trauma to the ovarian epithelium can lead to 
malignant transformation (Fathalla’s incessant ovu-
lation hypothesis). The second hypothesis suggests 
that persistent exposure of the ovary to endogenous 
and exogenous gonadotrophins in conjunction with 
secondarily elevated oestradiol concentration may be 
directly carcinogenic.110
A meta-analysis111 including seven case-con-
trol studies and three cohort studies showed reas-
suring results. The pooled data showed a signifi-
cantly elevated risk of ovarian cancer in subjects 
exposed to fertility medications when compared 
with general population controls (OR, 1.52; 95% 
CI, 1.18–1.97); such an increased risk was not ob
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Levels of evidence and grading of recommendations






Dopamine agonists are an effective treatment for anovulation related to hyperprolactinaemia. 
Evidence 1++, 
Grade A
Bromocriptine remains the treatment of choice for women undergoing ovulation induction because 
of extensive experience with this drug, while cabergoline and quinagolide are acceptable second-




CC increases ovulation and pregnancy rates with no increase in spontaneous abortion or congenital 




CC should be started at 50 mg daily for 5 days, at increments of 50 mg per cycle until ovulation 
occurs with a maximum dose of 150 mg daily. It should be continued for six cycles at ovulatory dose 
or until pregnancy occurs. 
Evidence 4, 
Grade D
Ovarian response should be monitored at least during the first cycle using pelvic ultrasound.
Evidence 4, 
Grade D
There is no significant difference in pregnancy rate or ovulation rate between CC and tamoxifen.
Evidence 1++, 
Grade A





The routine use of metformin either alone or in combination with CC in fertility treatment appears 
to have limited efficacy. 
Evidence 1++, 
Grade A
In a subgroup of PCOS patients who are obese or CC-resistant, co-treatment with metformin and 




Letrozole is as effective as CC in ovulation induction.
Evidence 1++, 
Grade A




Pulsatile GnRH Pulsatile GnRH therapy is indicated in patients with hypogonadotrophic anovulation, but its use 




Women with normogonadotrophic anovulation with anti-oestrogen resistance or failure can be 
offered ovulation induction with gonadotrophin. 
Evidence 3, 
Grade D
Human menopausal gonadotrophin, urinary FSH or recombinant FSH are all equally effective and do 
not differ in ovulation and pregnancy rates and risk of complications.
Evidence 1++, 
Grade A
For women with hypogonadotrophic hypogonadism, a preparation containing both FSH and LH 
should be used for ovulation induction.
Evidence 1++, 
Grade A








The use of GnRH agonist for pituitary downregulation should not be a routine but may be considered 




LOD has a comparable outcome in terms of ovulation rate and pregnancy rate when compared with 




LOD was not superior to CC as a first-line method of ovulation induction in PCOS women.
Evidence 1++, 
Grade A
CC = clomiphene citrate; FSH = follicle-stimulating hormone; GnRH = gonadotrophin-releasing hormone; LH = luteinizing hormone; LOD = laparoscopic ovarian drilling; PCOS = 
polycystic ovary syndrome.
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served when compared with subfertile controls not 
exposed to fertility medications (OR, 0.99; 95% CI, 
0.67–1.45). Indeed, cohort data comparing outcome 
in treated infertile patients with untreated subfer-
tile patients suggest that treated patients may tend 
to a lower incidence of ovarian cancer (OR, 0.67; 
95% CI, 0.32–1.41). It suggested that subfertility it-
self rather than the use of fertility drugs is the risk 
factor for developing ovarian cancer. Successful 
fertility treatment, which results in pregnancy, may 
actually reduce the cancer risk.
Similar reassuring findings were also ob-
tained from a recent large cohort study.112 In 54,362 
Danish women attending subfertility clinic during 
1963–1998, 156 women with invasive epithelial 
ovarian cancer were identified during a follow-up 
period of up to 42.6 years (median, 16.0 years). 
The risk of ovarian cancer was 46% higher than 
that of the general Danish population after adjust-
ment for parity. However, the overall risk of ovarian 
cancer was not significantly affected by the use of 
any fertility drug (RR, 1.03; 95% CI, 0.73–1.47), CC 
(RR, 1.14; 95% CI, 0.79–1.64), gonadotrophins (RR, 
0.93; 95% CI, 0.50–1.37) or GnRH (RR, 0.80; 95% 
CI, 0.42–1.51) or in combinations. Risk did not dif-
fer according to the number of cycles of use and 
length of follow-up since first use of drug or parity. 
Potential confounders including various causes of 
infertility and any use of oral contraceptives had 
not been shown to affect the risk estimates.
In three studies113–115 that have specifically ex-
amined the effect of fertility drug use on the risk of 
borderline tumours, a stronger association was ob-
served than with the risk of invasive tumours. The 
plausibility of these results is heightened by the 
finding that oestrogen receptor expression is a com-
mon feature of ovarian borderline tumours.114 And it 
may also suggest that the increased prevalence of 
borderline tumours compared to invasive cancer in 
a younger group of women. It should, however, be 
emphasized that the association between border-
line tumours and ovulation inducing drugs was not 
a consistent finding among different studies.
The relationship between subfertility treat-
ment and the risk of non-epithelial ovarian malig-
nancies is even less clear with limited data show-
ing conflicting results.116,117
In summary, findings to date on ovarian cancer 
risk associated with fertility drug treatment are re-
assuring but not definitive. A stronger association 
has been observed between fertility drug use and 
borderline tumours of ovary, though still not con-
sistent.
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